{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:54:52Z","timestamp":1784289292401,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbmt.2020.02.003","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T02:27:24Z","timestamp":1581647244000},"page":"1534-1542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse\/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain"],"prefix":"10.1016","volume":"26","author":[{"given":"Carmen","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-0134","authenticated-orcid":false,"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-3911","authenticated-orcid":false,"given":"Eduardo","family":"R\u00edos-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Zeberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Rodriguez-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosal\u00eda","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Barrenetxea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo-Dom\u00e9nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Espeso","family":"de Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.02.003_bib0001","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0002","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0003","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0004","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0005","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0007","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0008","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0009","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0012","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","article-title":"Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide","volume":"2","author":"Schoch","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0014","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0015","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"28","author":"Bek\u00f6z","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2020.02.003_bib0016","first-page":"5171","article-title":"Real-world data of nivolumab in classical Hodgkin lymphoma: results from the Italian expanded access programme","volume":"130","author":"Santoro","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","article-title":"Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation","volume":"115","author":"Manson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0018","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis","volume":"24","author":"Bair","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fphar.2019.00387","article-title":"Safety and efficacy of anti-PD-1 monoclonal antibodies in patients with relapsed or refractory lymphoma: a meta-analysis of prospective clinic trails","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ejh.13186","article-title":"Allogeneic hematopoietic stem cell transplantation in r\/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety","volume":"102","author":"Dada","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.02.003_bib0021","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2018-03-841262","article-title":"Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma","volume":"131","author":"Manson","year":"2018","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:54Z","timestamp":1761059574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120300872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1083879120300872"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse\/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}